People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ratio Therapeutics, Inc. | — | Pharmaceuticals | Series C | $50.7M | $540.0M | 2023 |
John W. Hoppin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John W. Hoppin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Allan W. Green | 1 | 1 |
| Shawn W. Hillier | 1 | 1 |
| Albert W. Holman | 1 | 1 |
| Matthias W. Friebe | 1 | 1 |
| Jacob W. Hesterman | 1 | 1 |
| John W. Babich | 1 | 1 |
| Reed W. Malleck | 1 | 1 |
| Scott W. Holbrook | 1 | 1 |
| John W. Garvey | 1 | 1 |
| Susan W. Whoriskey | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.